Table 3.

Timeline for Cancer Medicines Review

Date	Process or Event
January-May 2014	Methodology and process determined by core group from the Dana-Farber Cancer Institute and UICC.
May 31, 2014	UICC held planning meeting with core group plus new contributors at the Annual Meeting of the American Society of Clinical Oncology in Chicago, IL.
June-August 2014	A total of 22 adult cancers (including adult and pediatric cancers) as well as seven pediatric-specific cancers were included in the 2014 review process. Authors and reviewers were identified for solicitation of disease-based briefings.
September-October 2014	Invited authors from all over the world prepared and submitted disease-based briefings (including regimens) for the adult and pediatric cancers.
October-November 2014	Peer reviewers from all over the world reviewed briefings, including the treatment regimens.
November 2014	Dana-Farber Cancer Institute and UICC group compiled final drafts of briefings and prepared supplementary documents (eg, regulatory information, costing and price information, patent status, G-CSF briefing).
November 17-19, 2014	Cancer Medicines Working Group meeting held in Geneva, Switzerland, with more than a dozen participants from around the world. Each cancer briefing was reviewed in detail, and all input was recorded in real time. Long-term solutions were also discussed.
November-December 2014	Disease briefings were revised according to working group input and finalized for submission; 52 cancer medicines were recommended in the review, and 22 of those medicines were not yet included in the current WHO Model List.
December 15, 2014	Application submitted to the WHO Medicines Secretariat.
January 7, 2015	Application posted online on WHO Web site for public comment.
April 20-24, 2015	WHO to host 20th Expert Committee meeting for the selection of medicines to the 2015 Model List of Essential Medicines.

Abbreviations: G-CSF, granulocyte colony-stimulating factor; UICC, Union for International Cancer Control.